BACKGROUND: Variation in APOE genotype is a determinant of Alzheimer disease (AD), but the risk associated with variation in plasma apoE levels has yet to be determined. Here, we studied offspring with and without a parental history of AD to identify the effect of plasma apoE levels at middle age on the risk of late-onset AD. METHODS: Some 203 offspring from 92 families with a parental history of AD were compared with 197 offspring from 97 families without a parental history of AD. APOE genotypes and plasma apoE levels were assessed in all offspring. Difference in plasma apoE level between subjects with and without a parental history of AD was calculated using robust linear regression, both stratified and adjusted for APOE genotype. RESULTS: Offspring with a parental history of AD were more likely to be an APOE epsilon4 allele carrier (46% vs 21%, p < 0.001) than offspring without such a parental history. Mean plasma apoE levels strongly decreased from epsilon2 to epsilon3epsilon3 to epsilon4 carriers (p < 0.001). Offspring with a parental history of AD had lower plasma apoE levels than subjects without such a history, both in analyses adjusted for APOE genotype (difference: -0.21 mg/dL, p = 0.02) and when using standardized Z scores, when stratified for APOE genotype (difference: -0.22, p = 0.009). CONCLUSIONS: Our findings suggest that lower plasma apoE levels in middle age could be a risk factor for Alzheimer disease in old age, independent of APOE genotype.
BACKGROUND: Variation in APOE genotype is a determinant of Alzheimer disease (AD), but the risk associated with variation in plasma apoE levels has yet to be determined. Here, we studied offspring with and without a parental history of AD to identify the effect of plasma apoE levels at middle age on the risk of late-onset AD. METHODS: Some 203 offspring from 92 families with a parental history of AD were compared with 197 offspring from 97 families without a parental history of AD. APOE genotypes and plasma apoE levels were assessed in all offspring. Difference in plasma apoE level between subjects with and without a parental history of AD was calculated using robust linear regression, both stratified and adjusted for APOE genotype. RESULTS: Offspring with a parental history of AD were more likely to be an APOE epsilon4 allele carrier (46% vs 21%, p < 0.001) than offspring without such a parental history. Mean plasma apoE levels strongly decreased from epsilon2 to epsilon3epsilon3 to epsilon4 carriers (p < 0.001). Offspring with a parental history of AD had lower plasma apoE levels than subjects without such a history, both in analyses adjusted for APOE genotype (difference: -0.21 mg/dL, p = 0.02) and when using standardized Z scores, when stratified for APOE genotype (difference: -0.22, p = 0.009). CONCLUSIONS: Our findings suggest that lower plasma apoE levels in middle age could be a risk factor for Alzheimer disease in old age, independent of APOE genotype.
Authors: M Lindh; M Blomberg; M Jensen; H Basun; L Lannfelt; B Engvall; H Scharnagel; W März; L O Wahlund; R F Cowburn Journal: Neurosci Lett Date: 1997-06-27 Impact factor: 3.046
Authors: S M Laws; K Taddei; G Martins; A Paton; C Fisher; R Clarnette; J Hallmayer; W S Brooks; S E Gandy; R N Martins Journal: Neuroreport Date: 1999-03-17 Impact factor: 1.837
Authors: Kim G Jackson; Emma J Wolstencroft; Paul A Bateman; Parveen Yaqoob; Christine M Williams Journal: Br J Nutr Date: 2005-05 Impact factor: 3.718
Authors: U Beffert; J S Cohn; C Petit-Turcotte; M Tremblay; N Aumont; C Ramassamy; J Davignon; J Poirier Journal: Brain Res Date: 1999-10-02 Impact factor: 3.252
Authors: R Scacchi; G Gambina; M Ruggeri; M C Martini; G Ferrari; M Silvestri; R Schiavon; R M Corbo Journal: Neurosci Lett Date: 1999-01-04 Impact factor: 3.046
Authors: M J Artiga; M J Bullido; A Frank; I Sastre; M Recuero; M A García; C L Lendon; S W Han; J C Morris; J Vázquez; A Goate; F Valdivieso Journal: Hum Mol Genet Date: 1998-11 Impact factor: 6.150
Authors: A J Slooter; P de Knijff; A Hofman; M Cruts; M M Breteler; C Van Broeckhoven; L M Havekes; C M van Duijn Journal: Neurosci Lett Date: 1998-05-22 Impact factor: 3.046
Authors: John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole Journal: Arch Neurol Date: 2012-06
Authors: Robert Winker; Ina Lukas; Thomas Perkmann; Helmut Haslacher; Elisabeth Ponocny; Johann Lehrner; Dimiter Tscholakoff; Peter Dal-Bianco Journal: Wien Klin Wochenschr Date: 2010-11-15 Impact factor: 1.704
Authors: F Charles Brunicardi; Richard A Gibbs; David A Wheeler; John Nemunaitis; William Fisher; John Goss; Changyi Chen Journal: World J Surg Date: 2011-08 Impact factor: 3.352
Authors: Sterling C Johnson; Asenath La Rue; Bruce P Hermann; Guofan Xu; Rebecca L Koscik; Erin M Jonaitis; Barbara B Bendlin; Kirk J Hogan; Allen D Roses; Ann M Saunders; Michael W Lutz; Sanjay Asthana; Robert C Green; Mark A Sager Journal: Alzheimers Dement Date: 2011-07 Impact factor: 21.566
Authors: Timothy S Chang; Michael H Coen; Asenath La Rue; Erin Jonaitis; Rebecca L Koscik; Bruce Hermann; Mark A Sager Journal: J Int Neuropsychol Soc Date: 2012-02-10 Impact factor: 2.892
Authors: Madhav Thambisetty; Romina Tripaldi; Joanna Riddoch-Contreras; Abdul Hye; Yang An; James Campbell; Jitka Sojkova; Anna Kinsey; Steven Lynham; Yun Zhou; Luigi Ferrucci; Dean F Wong; Simon Lovestone; Susan M Resnick Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472